CTI Finds Pixuvri’s Conditional Authorization Is Not Enough To Win NICE Approval
In an early stage decision, NICE rejects Pixuvri for multiply relapsed or refractory aggressive non-Hodgkin's lymphoma, citing lack of evidence and cost-effectiveness.
In an early stage decision, NICE rejects Pixuvri for multiply relapsed or refractory aggressive non-Hodgkin's lymphoma, citing lack of evidence and cost-effectiveness.